Value of Amniotic Fluid Homocysteine Assay in Prenatal Diagnosis of Combined Methylmalonic Acidemia and Homocystinuria, Cobalamin C Type

Ting Chen
Shanghai Jiaotong University School of Medicine Xinhua Hospital Shanghai Institute for Pediatric Research
https://orcid.org/0000-0003-4212-9841

Lili Liang
Shanghai Jiaotong University School of Medicine Xinhua Hospital, Shanghai Institute for Pediatric Research

Huiwen Zhang
Shanghai Jiaotong University School of Medicine, Xinhua Hospital, Shanghai Institute for Pediatric Research

Jun Ye
Shanghai Jiaotong University School of Medicine Xinhua Hospital, Shanghai Institute for Pediatric Research

Wenjuan Qiu
Shanghai Jiaotong University School of Medicine Xinhua Hospital Shanghai Institute for Pediatric Research

Bing Xiao
Shanghai Jiaotong University School of Medicine Xinhua Hospital Shanghai Institute for Pediatric Research

Hong Zhu
Shanghai Jiaotong University School of Medicine Xinhua Hospital

Lei Wang
Shanghai Jiaotong University School of Medicine Xinhua Hospital

Feng Xu
Shanghai Jiaotong University School of Medicine Xinhua Hospital Shanghai Institute for Pediatric Research

Zhuwen Gong
Shanghai Jiaotong University School of Medicine Xinhua Hospital Shanghai Institute for Pediatric Research

Xuefan Gu
Shanghai Jiaotong University School of Medicine Xinhua Hospital Shanghai Institute for Pediatric Research

Lianshu Han (✉ hanlianshu@xinhuamed.com.cn)
Department of Pediatric Endocrinology and Genetic, Xinhua Hospital, Shanghai Institute for Pediatric Research, Shanghai Jiao Tong University School of Medicine, 1665 Kongjiang Road, Yangpu District, Shanghai 200092, China
https://orcid.org/0000-0003-4209-5119

Research

Keywords: Methylmalonic acidemia, Homocysteine, Prenatal diagnosis, MMACHC variant

Posted Date: November 20th, 2020

DOI: https://doi.org/10.21203/rs.3.rs-108786/v1
Abstract

Background: Combined methylmalonic acidemia and homocystinuria, cobalamin C type (cblC defect) is the most common inborn error of cobalamin metabolism. Even with rapid diagnosis and treatment, the long-term outcome remains poor. A reliable method for the prenatal diagnosis of cblC defect is needed for parental decisions regarding continuation of pregnancies of cblC defect fetuses.

Results: The between-day and within-day imprecision of Hcy assay were 1.60%∼5.87% and 1.11%∼4.31%, respectively. For the 248 at-risk fetuses, there were 63 affected fetuses with cblC defect and 185 unaffected fetuses. The levels of Hcy in 63 affected fetuses were significantly higher than those in 185 unaffected fetuses, without overlap between the affected and unaffected groups. Sixteen fetuses displayed inconclusive genetic results of MMACHC variants, in which seven fetuses were determined to be affected with elevated amniotic fluid levels of Hcy, C3, C3/C2 and MMA. The remaining nine fetuses were considered unaffected based on a normal amniotic fluid metabolite profile. The diagnostic sensitivities of Hcy and other characteristic metabolites including propionylcarnitine (C3), ratio of C3 to acetylcarnitine (C2; C3/C2), methylmalonic acid (MMA), and methylcitrate acid (MCA) in amniotic fluid were 100%, 87.50%, 100%, 85.71%, and 28.57%, respectively. The respective specificities were 92.05%, 100%, 100%, 97.73%, and 99.43%.

Conclusions: Hcy appears to be another sensitive characteristic metabolite biomarker for the prenatal diagnosis of cblC defect. The combination of Hcy assay with acylcarnitine and organic acid analysis is a fast, sensitive, and reliable prenatal diagnostic biochemical approach. This approach could overcome the challenge of the lack of genetic analysis for families with at-risk cblC defect fetuses.

Introduction

Combined methylmalonic acidemia and homocystinuria, cobalamin C type (cblC defect) is the most frequent genetic disorder of cobalamin metabolism [1]. The incidence of cblC defect ranges from 1:46,000 to 1:200,000 in European and American countries [2] and varies hugely from 1:3,220 to 1:21,488 in China [3-5]. The cblC defect is caused by variants in the MMACHC gene located in chromosome region 1p34.1 [6]. This defect impairs the conversion of cobalamin to methylcobalamin and adenosylcobalamin, resulting in the accumulation of homocysteine (Hcy) and methylmalonic acid (MMA) [7]. Based on the age of onset, cblC defect has two distinct phenotypes. Patients with early-onset present clinical symptoms that include feeding difficulties, progressive developmental delay, and hypotonia within the first year of life. Patients with late-onset exhibit relatively milder clinical features, such as behavioral disturbances and progressive neurological symptoms, later in life [8]. Despite the early diagnosis and effective treatment, the outcome is not always favorable, especially in early-onset cblC defect [9-11]. Thus, a reliable method for the prenatal diagnosis of cblC defect is needed to inform decisions regarding continuation of pregnancies of cblC defect fetuses.

To some extent, the combination of acylcarnitine analysis (characteristic metabolite biomarkers of propionylcarnitine (C3), the ratio of C3 to acetylcarnitine (C2; C3/C2) by liquid chromatography tandem mass spectrometry (LC-MS/MS), organic acid analyses of characteristic metabolite biomarkers of MMA, and methylcitrate acid (MCA) by gas chromatography mass spectrometry (GC-MS) is widely applied to the prenatal diagnosis of cblC defect [12, 13]. False positive and false negative results might also exist [14]. Thus, identifying another characteristic and sensitive biomarker to enhance the accuracy of metabolite analysis is desirable for the prenatal diagnosis of cblC defect. As cblC defect patients display a marked elevation of the plasma Hcy level [15,
an elevated Hcy level in amniotic uid (AF) might serve as a characteristic metabolite biomarker for the prenatal diagnosis of cblC defect. Furthermore, the combination of Hcy assay with acylcarnitine and organic acid analysis in AF could be more reliable and precise for the prenatal diagnosis of cblC defect.

Here, we present our findings with 248 at-risk pregnancies in the prenatal diagnosis of cblC defect by metabolite analysis of AF supernatants with/without genetic analysis of amniocytes. The aim was to elucidate the value of AF Hcy assay in the prenatal diagnosis of cblC defect.

Methods

Families and probands

In this study, 226 families (248 pregnancies) in which the probands were diagnosed as cblC defect were referred to our center for prenatal diagnosis from January 2010 to December 2019. The probands were diagnosed based on the symptoms, metabolite results of elevated blood levels of C3, C3/C2, MMA and MCA, and genetic analysis. Informed consent forms were signed by the parents or legal guardians of the study participants. This study was approved by the Ethics Committee of Xinhua Hospital (approval number XHEC-D-2020-131).

AF sample

In each case, 30 ml sample of AF was collected at 16-20 weeks of gestation from the pregnant woman. Of the 30 ml, 10 ml was used for DNA extraction. The cell-free AF supernatant was used for metabolite analysis. For this analysis, 13 μl was used for Hcy determination. 2 ml was used for organic acids analysis. 3 μl was used for quantitative acylcarnitine analysis. The remaining 20 ml of AF was cultured for karyotyping analysis, with the cultured amniocytes also used as a back-up.

Hcy determination of AF

Thirteen microliters of each cell-free AF sample was centrifuged at 3000 r/min for 5 min. The level of Hcy in AF was measured by an enzymatic cycling assay using the Hcy assay kit (Beijing Jiuqiang Biotechnology, Beijing, China) and following the manufacturer's protocol using an automatic analyzer (Hitachi, Tokyo, Japan). Between-day imprecision of Hcy assay was assessed by daily analysis for six days of a single lot of six AF samples with different Hcy levels. Within-day imprecision was assessed by measuring six replicates of six AF samples with different Hcy levels. Values of co-efficient of variation (CV) were calculated.

Acylcarnitine analysis of AF by LC-MS/MS

The level of acylcarnitine in each AF samples was analyzed using an API-4000 tandem mass spectrometer (Applied Biosystems, Foster City, CA, USA). Pretreatment of each AF sample and the LC-MS/MS operating conditions were previously reported [17]. Quantitative analysis of acylcarnitine was achieved using the ratio of the averaged ion intensity to that of the corresponding internal standards.

Organic acid analysis by GC-MS in AF

Organic acids in AF were analyzed using a single quadrupole GCMS-QP 2010 device (Shimadzu, Kyoto, Japan). Pretreatment of AF sample and GC-MS operating conditions were previously reported [17]. Quantitative analysis
of each organic acid was achieved using the relative peak area of each Q-ion to that of the corresponding internal standards.

**Direct MMACHC variant screening by Sanger sequencing**

Genomic DNA was extracted from the cultured amniocytes using the DNA extraction kit (TIANGEN Biotech, Beijing, China) according to the manufacturer's instruction. The conditions of the PCR reactions and analysis of DNA sequencing were previously described [18]. Nucleotide variations were identified using a reference sequence from Genbank (MMACHC: NM_015506). The novel variants were searched using the Mutalyzer website tool (https://mutalyzer.nl/) and the Human Gene Mutation Database.

**Diagnostic criteria**

Biochemical analysis: The reference ranges of Hcy, C3, C3/C2, MMA and MCA were 1.10-4.10 μmol/L, 0.30-4.00 μmol/L, 0.05-0.25, 0.00-1.00 mmol/mol Cr and 0.00-0.50 mmol/mol Cr, respectively. Fetuses with the above metabolites' levels higher than the upper limit of reference ranges were suggested as cblC defect.

Genetic analysis: Fetuses harbored homozygous variants or compound heterozygous variants of MMACHC were diagnosed as cblC defect.

**Statistical analysis**

Data analysis was performed using SPSS 24.0 (IBM, Chicago, Illinois). Data of detected metabolites were not normally distributed. The data are presented as median (range). The Mann-Whitney U test was applied to compare the difference of the levels of the metabolites between the affected and unaffected groups. A \( p \)-value less than 0.05 was considered statistically significant with a 95% confidence interval.

**Results**

The metabolite and genetic analyses involved 248 at-risk fetuses. The combination of these analyses identified 56 fetuses as affected, with 176 fetuses considered unaffected. Of the remaining 16 fetuses with unavailable causative variants in the probands, based on AF metabolites analysis alone, 7 fetuses were determined to be affected and diagnosed as cblC defect, and 9 fetuses were judged as unaffected.

**Biochemical analysis of AF metabolites**

The results of AF metabolites inferred that 63 of the totals of 248 fetuses were affected, with the remaining 185 unaffected (Table 1).

**Hcy level in AF**

The between-day imprecision of Hcy assay ranged from 1.60% to 5.87%. The within-day imprecision ranged between 1.11% and 4.31%. For the 185 unaffected fetuses, the median (range) level of Hcy was 2.70 μmol/L (0.00-5.80), which was significantly elevated in 63 affected fetuses with a median (range) level of 13.20 μmol/L (6.62-43.30) \( (p<0.0001; \) Table 1). There was no overlap of the Hcy level between the affected and unaffected fetuses. All the individual levels of Hcy in 63 affected fetuses were higher than the defined reference range. Among the 185 unaffected fetuses, the Hcy levels in 15 fetuses were above the upper limit of the reference range.
Acylcarnitine and organic acid levels in AF

As shown in Table 1, the median (range) levels of C3, C3/C2, MMA, and MCA in the AF of 185 unaffected fetuses were 1.08 (0.37-3.07) μmol/L, 0.09 (0.05-0.19), 0.00 (0.00-3.65) mmol/mol Cr, and 0.00 (0.00-0.56) mmol/mol Cr, respectively. These levels were notably increased in the 63 affected fetuses with the corresponding metabolite median (range) levels of 8.01 (2.09-19.58) μmol/L, 0.69 (0.28-1.17), 6.22 (0.00-144.40) mmol/mol Cr, and 0.00 (0.00-1.91) mmol/mol Cr, respectively (p<0.0001). Among the 63 affected fetuses, the C3 levels in 7 fetuses, MMA levels in 8 fetuses, and MCA levels in 44 fetuses were within the reference range. Among the 185 unaffected fetuses, the MMA levels in 4 fetuses and the MCA level in one fetus were above the upper limit of the reference range.

Genetic analysis of pathogenic variants in amniocyte DNA

Among the 248 at-risk fetuses, there were 232 fetuses with clear information concerning pathogenic variants in the probands and parents. For the 232 probands and 56 affected fetuses with clear MMACHC variants information, 59 cases harbored homozygous variants. The remaining 229 cases harbored compound heterozygous variants. Forty different variants were found. Of these, 9 variants were novel (see Additional file 1). The c.609G>A and c.658_660delAAG variants were the most common variants and accounted for 61.15% of disease alleles.

A total of 16 fetuses displayed inconclusive genetic results. Of these, 12 fetuses had only one causative mutation in the probands and there was a lack of available genetic information in the probands in 4 fetuses.

Comparison of metabolite results and genetic results

Among the 232 fetuses with clear MMACHC variants information in the probands and parents, genetic and metabolite results in 169 fetuses were completely consistent. Twelve fetuses were affected and the remaining 157 were unaffected. For 63 fetuses, the metabolite results of Hcy, C3, C3/C2, MMA, and MCA were incompletely consistent with the genetic results (Table 2). Of these 63 fetuses, 44 were affected and 19 were unaffected. For the 44 affected fetuses, compared with the genetic results, inconsistent findings were evident for C3 of 3 fetuses, MMA of one fetus, MCA of 29 fetuses, and C3 and MCA of 4 fetuses. For the remaining 7 fetuses, the MMA and MCA results were inconsistent. For the 19 unaffected fetuses, inconsistencies with the genetic results were evident for the Hcy of 14 fetuses, MMA of 4 fetuses, and MCA of one fetus.

Among the 16 fetuses with inconclusive genetic results, 7 were inferred to be affected. Of these 7 fetuses, the levels of all metabolites were elevated in 3 fetuses. In the remaining 4 fetuses, the levels of Hcy, C3, C3/C2, and MMA were elevated, while the MCA level was not. For the other 9 unaffected fetuses, the levels of all the metabolites were normal in 8, with only the Hcy level being increased in the remaining fetus. These 9 fetuses showed a normal phenotype at postnatal follow-up (see Additional file 2).

For the 232 fetuses with information of the pathogenic variants in the probands and parents, comparison of the metabolite results with genetic results revealed sensitivities of Hcy, C3, C3/C2, MMA, and MCA of 100%, 87.50%, 100%, 85.71%, and 28.57%, respectively. Their respective specificities were 92.05%, 100%, 100%, 97.73%, and 99.43%.

Discussion
The cblC defect is the most common subtype of vitamin B<sub>12</sub> metabolism [19]. Even with rapid diagnosis and effective treatment, the long-term outcome remains unsatisfactory, especially in patients with early onset, because of severe neurological sequelae [11]. The families of these patients suffer heavy economic burdens. Thus, prenatal diagnosis can provide important information in the decision about the pregnancy involving a fetus with the cblC defect, which could further reduce the social and family pressures from this disease.

For the prenatal diagnosis of cblC defect, metabolites can be measured and monitored in AF [20]. In a notable example, Ji et al [14] reported that metabolite analysis of acylcarnitines by LC-MS/MS and organic acids by GC-MS in AF could serve as rapid and reliable methods for the prenatal diagnosis of methylmalonic acidemia. However, their data of C3, C3/C2, MMA, and MCA sensitivity (95.1%, 100%, 100%, and 82.9%, respectively) and specificity (98.7%, 99.3%, 97.4%, and 96.7%, respectively) indicated the possibility of false positive results for the analyses of acylcarnitines and organic acids. Therefore, we aimed to find another effective biomarker to enhance the accuracy of metabolite analysis for prenatal diagnosis of the cblC defect.

Plasma total Hcy is recommended as an biomarker in the guideline for the diagnosis of cblC defect patients [21]. The Hcy assay of AF was performed in 9 at-risk fetuses for the prenatal diagnosis of cblC defect [22]. However, published reports concerning Hcy assay in AF for the prenatal diagnosis of cblC defect were all case reports or small series [22, 23]. Thus, it has been difficult to verify the reliability of the Hcy assay in the prenatal diagnosis of cblC defect. In this context, we retrospectively reviewed 248 at-risk fetuses with prenatal diagnostic data collected over a 10-year period to analyze the value of Hcy in the prenatal diagnosis of cblC defect. We first assessed the imprecision of Hcy assay, obtaining between-day CV values < 5.87% and within-day CV values < 4.31%. We observed no overlap of the Hcy level between the affected and unaffected fetuses. By contrast, C3/C2 displayed no overlap, while the levels of C3, MMA, and MCA all overlapped between the affected and unaffected fetuses.

Among the 232 fetuses with information concerning pathogenic variants in the probands and parents, results of the Hcy, C3, C3/C2, MMA, and MCA metabolites showed discrepancies in 63 fetuses. Consequently, a biochemical prenatal diagnosis of cblC defect in these fetuses could be uncertain based on any one of the metabolites. Nevertheless, we noted that Hcy levels and C3/C2 were consistent with genetic results in all affected fetuses, while in all unaffected fetuses, C3 and C3/C2 levels were completely consistent with the genetic results. Thus, by taking advantage of the 100% sensitivity, Hcy could help to decrease the false negative rate and obtain a more accurate biochemical prenatal diagnosis in the affected fetuses. However, in contrast with C3, C3/C2, MMA, and MCA, Hcy showed the lowest specificity of 92.05%, which might be associated with the selection of the reference range. Generally, the setting of the reference range is calculated by taking twice the standard deviation from the mean or considering certain percentiles of the normal population [24]. And the reference ranges of biomarkers for clinical diagnosis are commonly set as the 5th to 95th percentile of the normal population [25]. Thus, in our study, the reference range of Hcy was determined to be the 5th to 95th percentile of the Hcy values of 109 fetuses who were not at-risk for cblC defect. However, a previous report also suggested that a reference range based exclusively on normal population might result in many false positive results. Thus, the reference range might need adjustment in light of the overlap between the normal and disorder populations [26]. Therefore, depending on the increasing data of AF Hcy and the prenatal diagnosis of cblC defect, the reference range of prenatal Hcy level needs to be adjusted in the future to improve the low specificity of Hcy for the prenatal diagnosis of cblC defect. It is also worth noting that a total of 3 affected fetuses harboring the homozygous or heterozygous variant of c.482G>A displayed lower levels of Hcy (ranging from 6.62 to 8.9 μmol/L) compared to the other affected fetuses. The connection between the c.482G>A variant and Hcy level warrants a further investigation.
Genetic analysis is generally recognized as the gold standard for prenatal diagnosis [27, 28]. However, despite its accuracy, genetic analysis depends entirely on the complete genetic information of the proband and parents. For some at-risk fetuses without more than one causative variant found in the probands or when genetic analysis was not performed, this can hinder a precise prenatal diagnosis by genetic analysis alone. Presently, there were 12 fetuses without more than one causative variant and 4 fetuses whose genetic analysis were not performed. For these 16 fetuses, prenatal diagnosis was made depending on biochemical analysis alone. In a condition where the metabolite results were inconsistent, like the 5 fetuses in our study (Additional le 2), previous data indicates a preference for the more sensitive and specific biomarkers in the prenatal diagnosis [29]. Following this rule, among the 5 fetuses in the present study, 4 were diagnosed as the cblC defect. The one fetus diagnosed as unaffected showed a normal phenotype at the postnatal follow-up. Therefore, in this situation in which the genetic analysis alone did not permit a precise prenatal diagnosis, biochemical analysis for the supernatant of AF would provide fast and reliable results using a small amount of AF sample. The data could help families in making decisions concerning the pregnancies. This advantage was also observed in our previous reports on prenatal metabolite analysis in methylmalonic acidemia and glutaric acidemia-I [14, 30]. More importantly, for the biochemical prenatal diagnosis of cblC defect, the addition of Hcy could increase the accuracy and reliability, in comparison with the commonly used metabolite analysis of acylcarnitines and organic acids. Therefore, despite the accuracy of genetic analysis for prenatal diagnosis of cblC defect, the combination biochemical analysis of Hcy, C3, C3/C2, MMA, and MCA in AF appears to be valuable in the prenatal diagnosis of families for whom genetic results are not available.

Conclusions

The Hcy characteristic metabolite appears to be a sensitive biomarker for the prenatal diagnosis of cblC defect. The combination of the Hcy assay with acylcarnitine and organic acid analysis offers a fast, sensitive, and reliable prenatal diagnostic biochemical approach, which could overcome the challenge of the lack of genetic data for families at-risk of cblC defect fetuses.

Abbreviations

cblC defect: Combined methylmalonic acidemia and homocystinuria, cobalamin C type; AF: Amniotic fluid; LC-MS/MS: Liquid chromatography tandem mass spectrometry; GC-MS: Gas chromatography mass spectrometry; Hcy: Homocysteine; MMA: Methylmalonic acid; C3: Propionylcarnitine; C2: Acetylcarnitine; MCA: Methylcitrate acid.

Declarations

Ethics approval and consent to participate: This study was approved by the Ethics Committee of Xinhua Hospital (approval number XHEC-D-2020-131), and was conducted in agreement with the Declaration of Helsinki Principles.

Consent for publication: Not applicable.

Availability of data and materials: The datasets supporting the conclusions of this article are included within the article and its additional files.
Competing interests: The authors declare that they have no competing interests.

Funding: The National Key Research and Development Program of China (No. 2016YFC0901505)

Authors’ contributions: LH was responsible for the conception of the idea, acquisition of clinical data and supervision of the project. TC analyzed the initial clinical data and drafted the manuscript. LL and BX were major contributors in editing this manuscript. HZ and LW were responsible for the sample collection. TC, FX and ZG performed the measurements. All authors read and approved the final manuscript.

Acknowledgements: Not applicable.

References

1. Nogueira C, Marcao A, Rocha H, Sousa C, Fonseca H, Valongo C, et al. Molecular picture of cobalamin C/D defects before and after newborn screening era. J Med Screen. 2017;24:6-11.

2. Weisfeld-Adams JD, Morrissey MA, Kirmse BM, Salveson BR, Wasserstein MP, McGuire PJ, et al. Newborn screening and early biochemical follow-up in combined methylmalonic aciduria and homocystinuria, cblC type, and utility of methionine as a secondary screening analyte. Mol Genet Metab. 2010;99:116-23.

3. Guo K, Zhou X, Chen X, Wu Y, Liu C, Kong Q. Expanded Newborn Screening for Inborn Errors of Metabolism and Genetic Characteristics in a Chinese Population. Front Genet. 2018;9:122.

4. Han B, Cao Z, Tian L, Zou H, Yang L, Zhu W, et al. Clinical presentation, gene analysis and outcomes in young patients with early-treated combined methylmalonic acidemia and homocysteinemia (cblC type) in Shandong province, China. Brain Dev. 2016;38:491-7.

5. Zhou W, Li H, Wang C, Wang X, Gu M. Newborn Screening for Methylmalonic Acidemia in a Chinese Population: Molecular Genetic Confirmation and Genotype Phenotype Correlations. Front Genet. 2018;9:726.

6. Hu S, Mei S, Liu N, Kong X. Molecular genetic characterization of cblC defects in 126 pedigrees and prenatal genetic diagnosis of pedigrees with combined methylmalonic aciduria and homocystinuria. BMC Med Genet. 2018;19:154.

7. Pollini L, Tolve M, Nardecchia F, Galosi S, Carducci C, di Carlo E, et al. Multiple sclerosis and intracellular cobalamin defect (MMACHC/PRDX1) comorbidity in a young male. Mol Genet Metab Rep. 2020;22:100560.

8. Martinelli D, Deodato F, Dionisi-Vici C. Cobalamin C defect: natural history, pathophysiology, and treatment. J Inherit Metab Dis. 2011;34:127-35.

9. Zhou X, Cui Y, Han J. Methylmalonic acidemia: Current status and research priorities. Intractable Rare Dis Res. 2018;7:73-8.

10. Fischer S, Huemer M, Baumgartner M, Deodato F, Ballhausen D, Boneh A, et al. Clinical presentation and outcome in a series of 88 patients with the cblC defect. J Inherit Metab Dis. 2014;37:831-40.

11. Pastore A, Martinelli D, Piemonte F, Tozzi G, Boenzi S, Di Giovannoni G, et al. Glutathione metabolism in cobalamin deficiency type C (cblC). J Inherit Metab Dis. 2014;37:125-9.

12. Morel CF, Watkins D, Scott P, Rinaldo P, Rosenblatt DS. Prenatal diagnosis for methylmalonic acidemia and inborn errors of vitamin B12 metabolism and transport. Mol Genet Metab. 2005;86:160-71.

13. Yang C, Zhou C, Xu P, Jin X, Liu W, Wang W, et al. Newborn screening and diagnosis of inborn errors of metabolism: A 5-year study in an eastern Chinese population. Clin Chim Acta. 2020;502:133-8.
14. Ji X, Wang H, Ye J, Qiu W, Zhang H, Liang L, et al. Prenatal diagnosis of methylmalonic aciduria from amniotic fluid using genetic and biochemical approaches. Prenat Diagn. 2019;39:993-7.

15. Huemer M, Diodato D, Schwahn B, Schiff M, Bandeira A, Benoist JF, et al. Guidelines for diagnosis and management of the cobalamin-related remethylation disorders cblC, cblD, cblE, cblF, cblG, cblJ and MTHFR deficiency. J Inherit Metab Dis. 2017;40:21-48.

16. Jiang Y, Mistretta B, Elsea S, Sun Q. Simultaneous determination of plasma total homocysteine and methionine by liquid chromatography-tandem mass spectrometry. Clin Chim Acta. 2017;464:93-7.

17. Hasegawa Y, Igawa M, Kimura M, Shigematsu Y, Yamaguchi S. Prenatal diagnosis for organic acid disorders using two mass spectrometric methods, gas chromatography mass spectrometry and tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2005;823:13-7.

18. Zong Y, Liu N, Zhao Z, Kong X. Prenatal diagnosis using genetic sequencing and identification of a novel mutation in MMACHC. BMC Med Genet. 2015;16:48.

19. Wang X, Yang Y, Li X, Li C, Wang C. Distinct clinical, neuroimaging and genetic profiles of late-onset cobalamin C defects (cblC): a report of 16 Chinese cases. Orphanet J Rare Dis. 2019;14:109.

20. Carrillo-Carrasco N, Chandler RJ, Venditti CP. Combined methylmalonic acidemia and homocystinuria, cblC type. I. Clinical presentations, diagnosis and management. J Inherit Metab Dis. 2012;35:91-102.

21. Huemer M, Diodato D, Schwahn B, Schiff M, Bandeira A, Benoist JF, et al. Guidelines for diagnosis and management of the cobalamin-related remethylation disorders cblC, cblD, cblE, cblF, cblG, cblJ and MTHFR deficiency. J Inherit Metab Dis. 2017;40:21-48.

22. Zhang Y, Yang YL, Hasegawa Y, Yamaguchi S, Shi CY, Song JQ, et al. Prenatal diagnosis of methylmalonic aciduria by analysis of organic acids and total homocysteine in amniotic fluid. Chin Med J (Engl). 2008;121:216-9.

23. Merinero B, Perez-Cerda C, Garcia MJ, Chadeauf-Vekemans B, Kamoun P, Tonetti C, et al. Reliability of biochemical parameters used in prenatal diagnosis of combined methylmalonic aciduria and homocystinuria. Prenat Diagn. 1998;18:947-52.

24. Kerkhof P, Peace RA, Macfarlane PW. Sex- and Age-Related Reference Values in Cardiology, with Annotations and Guidelines for Interpretation. Adv Exp Med Biol. 2018;1065:677-706.

25. Liu Y, Ko EY, Wong KK, Chen X, Cheung WC, Law TS, et al. Endometrial microbiota in infertile women with and without chronic endometritis as diagnosed using a quantitative and reference range-based method. Fertil Steril. 2019;112:707-17.

26. McHugh D, Cameron CA, Abdennur JE, Abdulrahman M, Adair O, Al NS, et al. Clinical validation of cutoff target ranges in newborn screening of metabolic disorders by tandem mass spectrometry: a worldwide collaborative project. Genet Med. 2011;13:230-54.

27. Gupta N, Kabra M, Haberle J. Mutation analysis of Indian patients with urea cycle defects. Indian Pediatr. 2012;49:585-6.

28. Nogueira C, Aiello C, Cerone R, Martins E, Caruso U, Moroni I, et al. Spectrum of MMACHC mutations in Italian and Portuguese patients with combined methylmalonic aciduria and homocystinuria, cblC type. Mol Genet Metab. 2008;93:475-80.

29. Reitsma JB, Glas AS, Rutjes AW, Scholten RJ, Bossuyt PM, Zwadrmerman AH. Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews. J Clin Epidemiol. 2005;58:982-90.
30. Xiao B, Qiu W, Ye J, Zhang H, Zhu H, Wang L, et al. Prenatal Diagnosis of Glutaric Acidemia I Based on Amniotic Fluid Samples in 42 Families Using Genetic and Biochemical Approaches. Front Genet. 2020;11:496.

Tables

Table 1 Metabolite results of the 248 at-risk fetuses [median (range)]

| Group     | Number | Hcy (µmol/L) | C3 (µmol/L) | C3/C2 | MMA (mmol/mol Cr) | MCA (mmol/mol Cr) |
|-----------|--------|--------------|-------------|-------|-------------------|-------------------|
| Affected  | 63     | 13.20        | 8.01        | 0.69  | 6.22              | 0.00              |
|           |        | (6.62-43.30)*| (2.09-19.58)*| (0.28-1.17)*| (0.00-144.40)*    | (0.00-1.91)*      |
| Unaffected| 185    | 2.70         | 1.08        | 0.09  | 0.00              | 0.00              |
|           |        | (0.00-5.80)  | (0.37-3.07) | (0.05-0.19) | (0.00-3.65)      | (0.00-0.56)       |
| Reference ranges | | 1.10-4.10 | 0.30-4.00 | 0.05-0.25 | 0.00-1.00 | 0.00-0.50 |

*Significantly different (p<0.05) vs the unaffected group

Abbreviations: Hcy, homocysteine; C3, propionylcarnitine; C2, acetylcarnitine; MMA, methylmalonic acid; MCA, methylcitrate acid

Table 2 Prenatal data of 63 fetuses with one or more metabolites results inconsistent with genetic results
| No. | Variants of fetus (NM_015506) | Metabolites |
|-----|--------------------------------|-------------|
|     | Allele 1                        | Allele 2    | Hcy (μmol/L) | C3 (μmol/L) | C3/C2 | MMA (mmol/mol Cr) | MCA (mmol/mol Cr) |
| 1   | c.80A>G                         | c.658_660delAAG | Y            | N            | Y      | Y               | Y               |
| 2   | c.568insT                       | c.467G>A     | Y            | Y            | Y      | N               | Y               |
| 3   | c.80A>G                         | c.481C>T     | Y            | Y            | Y      | Y               | N               |
| 4   | c.481C>T                        | Exon1 deletion | Y            | Y            | Y      | Y               | N               |
| 5   | c.80A>G                         | c.609G>A     | Y            | N            | Y      | Y               | Y               |
| 6   | c.609G>A                        | c.656_658delAAG | Y            | Y            | Y      | N               | N               |
| 7   | c.394C>T                        | c.609G>A     | Y            | Y            | Y      | Y               | N               |
| 8   | c.609G>A                        | c.656_658delAAG | Y            | Y            | Y      | N               | Y               |
| 9   | c.482G>A                        | c.609G>A     | Y            | Y            | Y      | N               | N               |
| 10  | c.80A>G                         | c.609G>A     | Y            | Y            | Y      | Y               | N               |
| 11  | Exon1 deletion                  | c.599G>A     | Y            | Y            | Y      | Y               | N               |
| 12  | c.80A>G                         | c.658_660delAAG | Y            | N            | Y      | Y               | N               |
| 13  | c.455_457delCCC                 | c.658_660delAAG | Y            | Y            | Y      | N               | N               |
| 14  | c.609G>A                        | c.445_446delTG | Y            | Y            | Y      | Y               | N               |
| 15  | c.428C>T                        | c.658_660delAAG | Y            | Y            | Y      | Y               | N               |
| 16  | c.80A>G                         | c.609G>A     | Y            | Y            | Y      | Y               | N               |
| 17  | c.80A>G                         | c.609G>A     | Y            | Y            | Y      | Y               | N               |
| 18  | c.394C>T                        | c.445_446delTG | Y            | Y            | Y      | Y               | N               |
| 19  | c.445_446delTG                  | c.609G>A     | Y            | Y            | Y      | Y               | N               |
| 20  | c.609G>A                        | c.658_660delAAG | Y            | Y            | Y      | Y               | N               |
| 21  | c.57_58insT                     | c.609G>A     | Y            | Y            | Y      | Y               | N               |
| 22  | c.609G>A                        | Carry the same paternal allele as the proband | Y            | Y            | Y      | Y               | N               |
| 23  | c.217C>T                        | c.609G>A     | Y            | N            | Y      | Y               | N               |
| 24  | c.609G>A                        | c.626_627delTG | Y            | Y            | Y      | Y               | N               |
| 25  | c.445_446delTG                  | c.609G>A     | Y            | Y            | Y      | Y               | N               |
| 26  | c.609G>A                        | c.658_660delAGA | Y            | Y            | Y      | Y               | N               |
| 27  | c.394C>T                        | c.656_658delAGA | Y            | Y            | Y      | Y               | N               |
|   |   |   |   |
|---|---|---|---|
| 28 | c.609G>A | c.658_660delAGA | Y  Y  Y  Y  N  |
| 29 | c.80A>G | c.609G>A | Y  Y  Y  Y  N  |
| 30 | c.567dupT | c.99delA | Y  Y  Y  Y  N  |
| 31 | c.609G>A | c.658_660delAAG | Y  Y  Y  Y  N  |
| 32 | c.80A>G | c.609G>A | Y  Y  Y  N  N  |
| 33 | c.567dupT | c.609G>A | Y  Y  Y  Y  N  |
| 34 | c.482G>A | c.482G>A | Y  N  Y  Y  N  |
| 35 | c.445_446delTG | c.609G>A | Y  N  Y  Y  Y  |
| 36 | c.482G>A | c.482G>A | Y  N  Y  Y  N  |
| 37 | c.609G>A | c.609G>A | Y  Y  Y  N  N  |
| 38 | c.609G>A | c.609G>A | Y  Y  Y  Y  N  |
| 39 | c.609G>A | c.658_660delAAG | Y  Y  Y  Y  N  |
| 40 | c.609G>A | c.609G>A | Y  Y  Y  Y  N  |
| 41 | c.609G>A | c.609G>A | Y  Y  Y  Y  N  |
| 42 | c.609G>A | c.609G>A | Y  Y  Y  Y  N  |
| 43 | c.609G>A | c.658_660delAAG | Y  Y  Y  Y  N  |
| 44 | c.609G>A | c.658_660delAAG | Y  Y  Y  Y  N  |
| 45 | c.217C>T | - | N  Y  Y  Y  Y  |
| 46 | c.658_660delAAG | - | N  Y  Y  Y  Y  |
| 47 | c.658_660delAAG | - | N  Y  Y  Y  Y  |
| 48 | c.609G>A | - | N  Y  Y  Y  Y  |
| 49 | c.656_658delAGA | - | N  Y  Y  Y  Y  |
| 50 | c.658_660delAAG | - | N  Y  Y  Y  Y  |
| 51 | c.658_660delAAG | - | N  Y  Y  Y  Y  |
| 52 | - | - | N  Y  Y  Y  Y  |
| 53 | c.80A>G | - | N  Y  Y  Y  Y  |
| 54 | c.609G>A | - | N  Y  Y  Y  Y  |
| 55 | - | - | N  Y  Y  Y  Y  |
| 56 | - | - | N  Y  Y  Y  Y  |
| 57 | c.609G>A | - | N  Y  Y  Y  Y  |
| 58 | - | - | N  Y  Y  Y  Y  |
| 59 | - | - | Y  Y  Y  N  Y  |
|   |   |   |   |   |   |   |
|---|---|---|---|---|---|---|
| 60 | - | - | Y | Y | Y | N |
| 61 | c.609G>A | - | Y | Y | Y | N |
| 62 | c.658_660delAAG | - | Y | Y | Y | N |
| 63 | c.609G>A | - | Y | Y | Y | Y |

Y, metabolite result is consistent with the genetic results; N, metabolite result is inconsistent with the genetic results

Abbreviations: Hcy, homocysteine; C3, propionylcarnitine; C2, acetylcarnitine; MMA, methylmalonic acid; MCA, methylcitrate acid

**Supplementary Files**

This is a list of supplementary files associated with this preprint. Click to download.

- Additionalfile2.docx
- Additionalfile1.docx